

Christof Specker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8380111/publications.pdf>

Version: 2024-02-01

78
papers

3,877
citations

101543

36
h-index

144013

57
g-index

134
all docs

134
docs citations

134
times ranked

4324
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978.	0.9	49
2	Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review. <i>Zeitschrift Fur Rheumatologie</i> , 2021, 80, 1-9.	1.0	28
3	Response to: "Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic" by Fragoulis et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e61-e61.	0.9	6
4	Mission statement from rheumatologists in the German Society of Rheumatology (DGRh e.V.). <i>Zeitschrift Fur Rheumatologie</i> , 2021, 80, 10-12.	1.0	2
5	Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. <i>RMD Open</i> , 2021, 7, e001464.	3.8	82
6	Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in times of SARS-CoV-2 methodology, key messages and justifying information. <i>Rheumatology</i> , 2021, 60, 2128-2133.	1.9	10
7	Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines. <i>RMD Open</i> , 2021, 7, e001553.	3.8	23
8	The influence of the SARS-CoV-2 lockdown on patients with inflammatory rheumatic diseases on their adherence to immunomodulatory medication: a cross sectional study over 3 months in Germany. <i>Rheumatology</i> , 2021, 60, S151-S158.	1.9	11
9	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.9	151
10	A survey to evaluate knowledge, perceptions and attitudes toward COVID-19 vaccinations among rheumatologists in Germany. <i>Rheumatology International</i> , 2021, 41, 1949-1956.	3.0	4
11	Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination. <i>Zeitschrift Fur Rheumatologie</i> , 2021, 80, 33-48.	1.0	13
12	TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. <i>RMD Open</i> , 2021, 7, .	3.8	6
13	TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. <i>RMD Open</i> , 2021, 7, e001896.	3.8	22
14	ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 319-328.	0.8	1
15	The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
16	Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. <i>Lancet</i> , The, 2020, 396, 267-276.	13.7	78
17	National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. <i>RMD Open</i> , 2020, 6, e001332.	3.8	44
18	Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 840-842.	0.9	38

#	ARTICLE	IF	CITATIONS
19	Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1090-1097.	0.9	56
20	The German National Registry of Primary Immunodeficiencies (2012–2017). <i>Frontiers in Immunology</i> , 2019, 10, 1272.	4.8	71
21	IL-22 production of effector CD4+ T-cells is altered in SLE patients. <i>European Journal of Medical Research</i> , 2019, 24, 24.	2.2	6
22	BTLA Expression on Th1, Th2 and Th17 Effector T-Cells of Patients with Systemic Lupus Erythematosus Is Associated with Active Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4505.	4.1	24
23	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. <i>Journal of Clinical Medicine</i> , 2019, 8, 2013.	2.4	118
24	Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study. <i>Journal of Rheumatology</i> , 2019, 46, 279-284.	2.0	36
25	Swimming against the stream: the fishbowl discussion method as an interactive tool for medical conferences: experiences from the 11th European Lupus Meeting. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 713-714.	0.9	3
26	Timing of onset affects arthritis presentation pattern in antisynthetase syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 44-49.	0.8	30
27	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 71-80.	6.5	60
28	Pregnancy in systemic lupus erythematosus and antiphospholipid syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 397-414.	3.3	74
29	OP0099...Safety, tolerability and initial signs of efficacy of the fully human immunocytokine DEKAVIL (F8IL10): a novel therapeutic approach for rheumatoid arthritis. , 2017, , .		1
30	Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions. <i>Deutsches Ar&#x0308;rztblatt International</i> , 2017, 114, 197-203.	0.9	34
31	<i>Rheumatologie</i> . , 2017, , 469-497.		0
32	First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBServe Germany Study. <i>Rheumatology and Therapy</i> , 2016, 3, 271-290.	2.3	60
33	Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome. <i>Medicine (United States)</i> , 2015, 94, e1144.	1.0	133
34	German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. <i>Rheumatology International</i> , 2014, 34, 1-9.	3.0	33
35	Increased percentages of PD-1 on CD4 ⁺ T cells is associated with higher INF- γ production and altered IL-17 production in patients with systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 2014, 43, 307-313.	1.1	31
36	Utility of combined high-resolution bone SPECT and MRI for the identification of rheumatoid arthritis patients with high-risk for erosive progression. <i>European Journal of Radiology</i> , 2013, 82, 374-379.	2.6	18

#	ARTICLE	IF	CITATIONS
37	Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in Germany (GRAID). <i>Lupus</i> , 2013, 22, 1142-1149.	1.6	74
38	Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. <i>Rheumatology</i> , 2013, 52, 1070-1076.	1.9	77
39	Arthroscopic synovectomy and radiosynoviorthesis: a treatment option for recurrent arthritis symptoms in patients with pachydermoperiostosis. <i>Reumatismo</i> , 2013, 65, 82-5.	0.9	8
40	Aberrant expression of the negative costimulator PD-1 on T cells in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2012, 51, 1188-1197.	1.9	52
41	Efficacy and Safety of Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: Results from a German Registry (GRAID). <i>Journal of Rheumatology</i> , 2012, 39, 2153-2156.	2.0	32
42	Current state of evidence on “off-label” therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland – a consensus report. <i>Lupus</i> , 2012, 21, 386-401.	1.6	71
43	Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. <i>Lupus</i> , 2012, 21, 1183-1189.	1.6	48
44	Mutations in the prostaglandin transporter encoding gene <i>SLCO2A1</i> Cause primary hypertrophic osteoarthropathy and isolated digital clubbing. <i>Human Mutation</i> , 2012, 33, 660-664.	2.5	69
45	Molecular imaging of cartilage damage of finger joints in early rheumatoid arthritis with delayed gadolinium-enhanced magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2012, 64, 394-399.	6.7	42
46	Synovitis and bone inflammation in early rheumatoid arthritis: high-resolution multi-pinhole single-photon-emission computed tomography (mph-spect) versus magnetic resonance imaging (mri). <i>Diagnostic and Interventional Radiology</i> , 2012, 19, 20-4.	1.5	16
47	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). <i>Arthritis Research and Therapy</i> , 2011, 13, R75.	3.5	170
48	An ask the expert service on a rheumatology web site: Who were the users and what did they look for?. <i>Arthritis Care and Research</i> , 2011, 63, 604-611.	3.4	14
49	Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2010, 12, R150.	3.5	54
50	Hypogonadism in Wegener's granulomatosis. <i>Scandinavian Journal of Rheumatology</i> , 2008, 37, 365-369.	1.1	11
51	Self-assessments of patients via Tablet PC in routine patient care: comparison with standardised paper questionnaires. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1739-1741.	0.9	90
52	CD4+CD25+ T-cell populations expressing CD134 and GITR are associated with disease activity in patients with Wegener's granulomatosis. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 161-171.	0.7	43
53	Rituximab as a Treatment Option for Refractory Endogenous Anterior Uveitis. <i>Ophthalmic Research</i> , 2007, 39, 184-186.	1.9	54
54	Peripheral Circulating Activated B-cell Populations are Associated with Nephritis and Disease Activity in Patients with Systemic Lupus Erythematosus. <i>Scandinavian Journal of Immunology</i> , 2007, 66, 584-590.	2.7	26

#	ARTICLE	IF	CITATIONS
55	CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus. <i>Clinical and Experimental Immunology</i> , 2006, 145, 235-242.	2.6	44
56	Hereditary Periodic Fever With Systemic Amyloidosis: Is Hyper-IgD Syndrome Really a Benign Disease?. <i>American Journal of Kidney Diseases</i> , 2006, 48, e41-e45.	1.9	27
57	Antiphospholipid syndrome in cardiac surgery—“an underestimated coagulation disorder?”†. <i>European Journal of Cardio-thoracic Surgery</i> , 2005, 28, 133-137.	1.4	34
58	Health care and burden of illness in systemic lupus erythematosus compared to rheumatoid arthritis: results from the national database of the German Collaborative Arthritis Centres. <i>Lupus</i> , 2004, 13, 529-536.	1.6	28
59	Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus. <i>Rheumatology International</i> , 2003, 23, 319-323.	3.0	10
60	Jaccoud's arthropathy in systemic lupus erythematosus: Differentiation of deforming and erosive patterns by magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2003, 48, 157-165.	6.7	113
61	Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2002, 46, 600-603.	1.2	56
62	OP0074—Platelet cd40 l expression in sle and antiphospholipid syndrome. , 2001, , .		0
63	FRIO178—Followup of platelet activation in a patient with antiphospholipid syndrome upon tirofiban treatment. , 2001, , .		0
64	Relapsing polychondritis in childhood - case report and short review. <i>Rheumatology International</i> , 2000, 19, 231-234.	3.0	27
65	Cerebral microembolism, a disease marker for ischemic cerebrovascular events in the antiphospholipid syndrome of systemic lupus erythematosus?. <i>Acta Neurologica Scandinavica</i> , 1999, 99, 356-361.	2.1	32
66	RheumaNet—a novel Internet-based rheumatology information network in Germany. <i>Rheumatology</i> , 1998, 37, 1015-1019.	1.9	12
67	Detection of cerebral microemboli in APS — Introducing a novel investigation method and implications of analogies with carotid artery disease. <i>Lupus</i> , 1998, 7, 75-80.	1.6	16
68	High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosus. <i>Lupus</i> , 1998, 7, 113-118.	1.6	194
69	Cerebral microemboli in patients with antiphospholipid syndrome. <i>Lupus</i> , 1997, 6, 638-644.	1.6	44
70	Acquired factor VIII inhibitors in nonhemophilic patients. <i>Annals of Hematology</i> , 1997, 74, 89-93.	1.8	68
71	Significance of antibodies to cardiolipin in unselected patients with systemic lupus erythematosus: clinical and laboratory associations. <i>Rheumatology International</i> , 1995, 15, 23-29.	3.0	33
72	Cerebral Microembolism in Patients With Sneddon's Syndrome. <i>Archives of Neurology</i> , 1995, 52, 271-275.	4.5	43

#	ARTICLE	IF	CITATIONS
73	Antiphospholipid Antibodies in Systemic Lupus Erythematosus and Sneddon's Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 1994, 20, 55-63.	2.7	16
74	HLA class II genes and antibodies against recombinant U1-nRNP proteins in patients with systemic lupus erythematosus. <i>Rheumatology International</i> , 1994, 14, 63-69.	3.0	7
75	Antiphospholipid syndrome complicating chronic graft-versus-host disease after allogeneic bone marrow transplantation. <i>American Journal of Hematology</i> , 1994, 47, 143-144.	4.1	15
76	Glucocorticoid receptors in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1992, 35, 740-744.	6.7	101
77	Immunoglobulin allotypes are not associated with HLA-antigens, autoantibodies and clinical symptoms in systemic lupus erythematosus. <i>Rheumatology International</i> , 1991, 11, 179-182.	3.0	4
78	Immunoglobulin allotypes in systemic lupus erythematosus—results of a central European multicenter study. SLE Study Group. <i>Experimental and Clinical Immunogenetics</i> , 1991, 8, 11-5.	1.2	5